Alec Stranahan
Stock Analyst at B of A Securities
(0.74)
# 3,672
Out of 4,711 analysts
24
Total ratings
46.67%
Success rate
-23.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.85 | +110.53% | 2 | Nov 25, 2024 | |
| DAWN Day One Biopharmaceuticals | Upgrades: Buy | $11 → $24 | $12.79 | +87.65% | 3 | Aug 1, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $44.06 | +24.83% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $8.70 | +106.90% | 3 | Jun 14, 2024 | |
| ERAS Erasca | Downgrades: Neutral | $11 → $6 | $2.54 | +136.22% | 1 | Jan 5, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $118 → $140 | $164.83 | -15.06% | 3 | May 25, 2023 | |
| XNCR Xencor | Initiates: Buy | $42 | $24.13 | +74.06% | 1 | May 19, 2023 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $6 → $12 | $8.28 | +44.93% | 4 | May 15, 2023 | |
| TGTX TG Therapeutics | Maintains: Underperform | $5 → $6 | $32.20 | -81.37% | 2 | Dec 29, 2022 | |
| HOOK HOOKIPA Pharma | Downgrades: Underperform | $60 → $5 | $2.02 | +147.52% | 1 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $35.59 | +26.44% | 1 | Dec 1, 2022 |
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.85
Upside: +110.53%
Day One Biopharmaceuticals
Aug 1, 2024
Upgrades: Buy
Price Target: $11 → $24
Current: $12.79
Upside: +87.65%
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $44.06
Upside: +24.83%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $8.70
Upside: +106.90%
Erasca
Jan 5, 2024
Downgrades: Neutral
Price Target: $11 → $6
Current: $2.54
Upside: +136.22%
Krystal Biotech
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $164.83
Upside: -15.06%
Xencor
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $24.13
Upside: +74.06%
Y-mAbs Therapeutics
May 15, 2023
Maintains: Neutral
Price Target: $6 → $12
Current: $8.28
Upside: +44.93%
TG Therapeutics
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $32.20
Upside: -81.37%
HOOKIPA Pharma
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $2.02
Upside: +147.52%
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $35.59
Upside: +26.44%